1 | A Study of Anlotinib in Patients With Hepatocellular Carcinoma | • Drug: Anlotinib | 2 | 60 | 18 Years to 75 Years (Adult, Older Adult) | all |
2 | Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma | • Drug: Anlotinib | 2 | 28 | 18 Years to 75 Years (Adult, Older Adult) |
3 | Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | • Drug: Anlotinib and Sintilimab injection | 2 | 20 | 18 Years to 70 Years (Adult, Older Adult) |
4 | A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) | • Biological: AK105 • Drug: Anlotinib Hydrochloride | 2 | 30 | 18 Years to 75 Years (Adult, Older Adult) |
5 | Adjuvant Therapy With Anlotinib for HCC | • Drug: Anlotinib Hydrochloride | 2 | 0 | 18 Years to 75 Years (Adult, Older Adult) |
6 | A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) | • Drug: AK105 Injection • Drug: Anlotinib Hydrochloride Capsules • Drug: Sorafenib Tosylate Tablets | 3 | 648 | 18 Years to 75 Years (Adult, Older Adult) |
7 | A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma | • Drug: TQB2450 injection • Drug: Anlotinib | 1,2 | 60 | 18 Years to older (Adult, Older Adult) |
8 | TACE Combined With Penpulimab and Anlotinib for Advanced HCC | • Drug: TACE + penpulimab + anlotinib vs. penpulimab + anlotinib | 2,3 | 109 | 18 Years to 80 Years (Adult, Older Adult) |
9 | TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Respectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis | • Drug: Anlotinib hydrochloride capsules# TQB2450 injection | 1,2 | 20 | 18 Years to 75 Years (Adult, Older Adult) |
10 | A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence | • Drug: Anlotinib Hydrochloride | 1,2 | 28 | 18 Years to 75 Years (Adult, Older Adult) |
11 | Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC | • Drug: Anlotinib • Device: TACE + RFA | 2 | 48 | 18 Years to 75 Years (Adult, Older Adult) |
12 | Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence | • Drug: Anlotinib Hydrochloride • Procedure: TACE | 2 | 48 | 18 Years to 75 Years (Adult, Older Adult) |
13 | Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab, JS001) Detected on the NGS Platform Combined With Anlotinib | • Drug: Anlotinib; Toripalimab | 2 | 30 | 18 Years to 75 Years (Adult, Older Adult) |
14 | TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients | • Device: TACE • Drug: Anlotinib Hydrochloride | 2 | 40 | 18 Years to 75 Years (Adult, Older Adult) |
15 | Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | • Drug: Anlotinib | - | 40 | 18 Years to 75 Years (Adult, Older Adult) |
16 | Anlotinib for Hepatocellular Carcinoma | • Drug: Anlotinib | - | 200 | Child, Adult, Older Adult |
17 | TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection | • Drug: TQB2450 injection • Drug: Anlotinib hydrochloride capsules | 2 | 37 | 18 Years to 75 Years (Adult, Older Adult) |
18 | HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection | • Drug: HAIC + TQB2450 + Anlotinib | 2 | 70 | 18 Years to 75 Years (Adult, Older Adult) |
19 | Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC | • Drug: Anlotinib and TQB2450 solution • Drug: TQB2450 solution | 3 | 80 | 18 Years to 80 Years (Adult, Older Adult) |
20 | Novel Treatment of Advanced Hepatocellular Carcinoma | • Drug: Anlotinib Hydrochloride Capsules • Drug: Arginine hydrochloride • Drug: levamisole | 3 | 300 | 18 Years to 65 Years (Adult, Older Adult) |
21 | TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC | • Drug: PD-1/PD-L1 inhibitors + VEGF- TKI/bevacizumab • Procedure: TACE | - | 474 | 18 Years and older (Adult, Older Adult) |
22 | TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC | • Drug: PD-1/PD-L1 inhibitors + VEGF-TKI/bevacizumab • Procedure: TACE | - | 220 | 18 Years and older (Adult, Older Adult) |